Floatz logo

Valchlor

Mycosis Fungoides

Rochester Skin Lymphoma Medical Group, PLLCPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

51 Active assets in the Mycosis Fungoides cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Virogen Biotechnology Inc.
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
Mayo Clinic
Phase 4BBB
METHOTREXATE
Polish Lymphoma Research Group
Phase 4BBB

View all 50 →

Same molecule, other indications

Valchlor is also rated in:

Cutaneous T-cell LymphomaDormant
B
Indicative ·
57 / 100
View asset →
Cutaneous T-cell Lymphoma Stage IDormant
B
Indicative ·
57 / 100
View asset →
Folliculotropic Mycosis FungoidesDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →